Congress tightens hospice oversight with 5-year enrollment freeze and payment restructuring

What it does

This bill overhauls Medicare hospice oversight and payment. It imposes a 5-year moratorium on new hospice program enrollment (with exemptions for underserved areas), requires enhanced audits and surveys of new and high-risk programs, mandates physician independence in terminal illness certifications, expands who can certify terminal illness, and restructures hospice payment rates to separate routine home care into per-diem and per-visit components starting in 2030, with enhanced payments for palliative chemotherapy, radiation, dialysis, and blood transfusions. It also requires advance notice of ownership changes, face-to-face recertification encounters, and expanded patient disclosures.

Why we flagged it

The bill's core mechanism is a comprehensive regulatory tightening of hospice program enrollment, quality oversight, and payment structure. It is not primarily a deregulation, tax cut, or narrow carve-out, but rather a multi-faceted federal control and restructuring of a Medicare benefit.

What the text implies

• The 5-year enrollment moratorium may create de facto market consolidation: existing hospice programs face less competition, potentially reducing pressure to improve quality or lower costs, while new entrants (except in underserved areas) are locked out.
• Payment restructuring for specialized palliative care (chemotherapy, dialysis, transfusions) at 400% of 2027 rates may incentivize hospice programs to pursue these higher-margin services, potentially shifting focus away from traditional comfort care.
• Wage-adjusted caps and per-visit payment models create administrative complexity and may disadvantage rural or low-density hospice programs with higher per-visit costs.
• Requirement for oncologist/nephrologist involvement in specialized palliative care plans may limit access in areas with few specialists, effectively restricting the availability of these services despite enhanced payment.
• Technical expert panels and audit requirements impose significant compliance burden, favoring larger hospice chains with compliance infrastructure over smaller independent programs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain stronger oversight of hospice quality (surveys, audits, physician independence, patient disclosures) and access to specialized palliative care (chemotherapy, dialysis, transfusions) with enhanced payment. However, the 5-year enrollment moratorium may reduce hospice availability in some areas, and payment restructuring creates complexity that could affect access or cost-sharing depending on implementation.

Who stands to gain

• Existing hospice programs (reduced competition from moratorium)
• Larger hospice chains (compliance infrastructure advantage)
• Oncologists and nephrologists (required for specialized palliative care oversight)
• Medicare administrative contractors and medical review contractors (expanded audit and review work)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Secretary of Health and Human Services, Medicare administrative contractors, Recovery audit contractors, Supplemental medical review contractors, Uniform program integrity contractors, Hospice programs, Federal Hospital Insurance Trust Fund, Inspector General of the Department of Health and Human Services

Where it stands

• Mar 17, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 17, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 5 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $2,090,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Mark Warner, the sponsor, reported $2,246,650 in PAC receipts in the 2026 cycle. $7,500 of that came from 1 PAC tied to these lobbying clients.

• Abbott Laboratories — $1,150,000 on 1 filing
• National Alliance for Care at Home (formerly Natl Assn for Home Care & Hospice) — $610,000 on 1 filing
• Vitas Healthcare Corporation — $230,000 on 1 filing
• The National Alliance for Care at Home — $50,000 on 1 filing
• Vitas Healthcare — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.